• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Glaucoma Practices Adapted During COVID-19

Article

A literature review finds that glaucoma care changed for the better during the COVID-19 pandemic.

The COVID-19 pandemic has had a significant on all of healthcare. Glaucoma specialists worldwide, specifically, have implemented major changes in their practices. These include using single diagnostic instrument, new disinfection protocols, reorganizing patient flow to limit those in the waiting room and creating a hybrid model of care, according to a recent review in Current Opinion in Ophthalmology.

Glaucoma, which is characterized by damage to the optic nerve, is a common cause of blindness. It is estimated that about 76 million people in the world suffer from glaucoma, and that number is expected to reach 111.8 million by 2040. In the United States, about three milion people are affected by the disease.

Kateki Vinod, M.D.

Kateki Vinod, M.D.

Paul A. Sidoti, M.D.

Paul A. Sidoti, M.D.

Investigators Kateki Vinod, M.D., and Paul A. Sidoti, M.D., conducted a review of reports from 2020 and 2021 to determine how glaucoma practices adapted during the COVID-19 pandemic. Vinod is an assistant professor of ophthalmology at the Icahn School of Medicine at Mount Sinai. Sidoti is professor and deputy chair for clinical affairs for the Department of Ophthalmology at New York Eye and Ear Infirmary of Mount Sinai.

“Beyond the pandemic, these developments in care delivery will allow for improved access to services and a reduction in existing disparities within our communities,” they wrote.

COVID-19 presented challenges for glaucoma practices. It remains unclear whether COVID-19 can be transmitted via the ocular surface, investigators said. Practices, however, began using disposable diagnostic instruments, which increased safety compared with reusable instruments that may not have been properly disinfected. One study reviewed by Vinod and Sidoti found that disposable GAT tips used to measure intraocular pressure were cost-effective when compared with the additional expense of disinfecting reusable tips.

Vinod and Sidoti indicated that disposable tip covers are also available for ultrasound pachymeter, which is used to measure the thickness of the cornea.

They also found that glaucoma practices have adopted a hybrid care solution where technicians conducted diagnostic testing and patients then met virtually with glaucoma specialists. But early in the pandemic, ophthalmologists were among the least frequent users of telemedicine. Less than 10% of ophthalmologists used telehealth, compared with 67.7% for endocrinologist and 50% for cardiologists, according to one analysis cited by Vinod and Sidoti. This study analyzed telemedicine use among 16.7 million beneficiaries with commercial insurance and Medicare Advantage over the first 13 weeks of the pandemic.

The hybrid approach, they said, was first used in the United Kingdom 10 years before the pandemic, and during the pandemic, it was adopted in various forms. Early in the pandemic, some practices used drive-through IOP checks followed by virtual visits with glaucoma specialists.

In another study within the Singapore National Eye Center's glaucoma clinic, 40% of patients had stable disease and could benefit through use of the hybrid model. In this study, 94.8% of patients were satisfied with this model.

Vinod and Sidoti said currently the hybrid model is being used by practices as a supplement to in-person visits. “Its future expansion and sustainability will rely on numerous factors including favorable reimbursement structures, ease of use, acceptance by physicians and patients, and further validation of home monitoring devices,” they said.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.